Skip to main content
. 2020 Oct 14;15(10):e0240517. doi: 10.1371/journal.pone.0240517

Fig 1. Effect of AMPK agonists on cell viability.

Fig 1

Mitochondrial-deficient patient fibroblasts were treated with AMPK agonists A-769662, PT1, C24, ZLN024, AICAR, DMSO (vehicle), or PBS (untreated control). Cell lines are from patients with a defect in (A) SURF1, (B) COX10, (C) CI, and (D) POLG. Viability was assessed by calcein AM fluorescence intensity. Experiments were performed in triplicate on at least three separate occasions and also included fibroblasts from a healthy control (“Normal”). Bars represent standard error of the mean. Asterisks represent statistical significance (*p<0.05).